OncoMatch/Clinical Trials/NCT06354140

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

Is NCT06354140 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tegafur for esophageal squamous cell carcinoma.

Phase 2RecruitingDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT06354140Data as of May 2026

Treatment: Tegafur — To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage YPT1N0M0, YPT2N0M0, YPT3N0M0, YPT4AN0M0 (8th UICC-TNM)

thoracic esophageal squamous cell carcinoma patients with residual pathologic primary site and lymph node positive (ypT1-4aN0M0) after surgery (8th UICC-TNM stage)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: immunotherapy — neoadjuvant

neoadjuvant immunotherapy combined with chemotherapy

Must have received: chemotherapy — neoadjuvant

neoadjuvant immunotherapy combined with chemotherapy

Must have received: surgery — radical resection

The operation was radical resection

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify